Coder-rony commited on
Commit
a55f839
·
verified ·
1 Parent(s): 257446c

validated shard 368

Browse files
Files changed (1) hide show
  1. validated/shard_00368.jsonl +4 -0
validated/shard_00368.jsonl ADDED
@@ -0,0 +1,4 @@
 
 
 
 
 
1
+ {"session_id": "atlas-7b452149ff", "tier": "text", "task_instruction": "Determine the prognosis of a patient with secondary AML arising from chemotherapy for a previous malignancy.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "The patient has secondary AML resulting from chemotherapy treatment for a previous malignancy.", "image_path": null, "audio_path": null}, "reasoning": "Secondary AML, which arises after chemotherapy, is mentioned to have a worse prognosis.", "action": {"type": "text_response", "value": "Recognize that the prognosis is worse due to the nature of secondary AML."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "The passage also notes that secondary AML is associated with a high rate of unfavorable cytogenetic abnormalities.", "image_path": null, "audio_path": null}, "reasoning": "Unfavorable cytogenetic abnormalities are linked to a poorer prognosis in AML patients.", "action": {"type": "text_response", "value": "Conclude that the unfavorable chromosomal changes contribute to the worse outcome."}, "refers_back_to": null}], "task_complexity": "low", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-18", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "AML which arises from a pre @-@ existing myelodysplastic syndrome ( MDS ) or myeloproliferative disease ( so @-@ called secondary AML ) has a worse prognosis , as does treatment @-@ related AML arising after chemotherapy for another previous malignancy . Both of these entities are associated with a high rate of unfavorable cytogenetic abnormalities .", "_validation_note": "Both steps have logical reasoning, correct conclusions, and coherent actions."}
2
+ {"session_id": "atlas-9b31797527", "tier": "text", "task_instruction": "Identify the factors influencing the prognosis of a cancer patient.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "The passage states that age over 60 years is associated with poorer outcomes.", "image_path": null, "audio_path": null}, "reasoning": "Advanced age may lead to reduced physiological resilience, impacting treatment efficacy and recovery potential.", "action": {"type": "text_response", "value": "Conclude that age over 60 is a significant factor in prognosis."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "Elevated lactate dehydrogenase levels are linked to poorer outcomes.", "image_path": null, "audio_path": null}, "reasoning": "High LDH levels often indicate tissue damage or disease severity, which can worsen prognosis.", "action": {"type": "text_response", "value": "Identify elevated LDH as a critical factor affecting prognosis."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "Performance status, encompassing physical condition and activity level, is a major factor.", "image_path": null, "audio_path": null}, "reasoning": "A patient's ability to perform daily activities reflects their overall health and capacity to handle treatments, thereby influencing prognosis.", "action": {"type": "text_response", "value": "Recognize performance status as a key determinant of prognosis."}, "refers_back_to": null}], "task_complexity": "low", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-18", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "In some studies , age > 60 years and elevated lactate dehydrogenase level were also associated with poorer outcomes . As with most forms of cancer , performance status ( i.e. the general physical condition and activity level of the person ) plays a major role in prognosis as well .", "_validation_note": "<reason> -- The reasoning logically supports the conclusion, is correct and sensible, and is coherent."}
3
+ {"session_id": "atlas-4364c0520d", "tier": "text", "task_instruction": "Identify the mutations associated with improved or worsened prognosis in AML patients with normal cytogenetics and determine their inclusion in validated risk stratification schemas.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "The passage mentions FLT3 ITD, NPM1, CEBPA, and c-KIT as molecular alterations under study for their prognostic impact in AML.", "image_path": null, "audio_path": null}, "reasoning": "FLT3 ITD is linked to a poorer prognosis, while NPM1 and biallelic CEBPA are associated with improved outcomes, especially in patients with normal cytogenetics.", "action": {"type": "text_response", "value": "Identify that FLT3 ITD worsens prognosis, while NPM1 and CEBPA improve it."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "These mutations are part of validated international risk stratification schemas.", "image_path": null, "audio_path": null}, "reasoning": "The passage states that NPM1 and CEBPA are used in current risk stratification algorithms, indicating their inclusion in validated schemas.", "action": {"type": "text_response", "value": "Confirm that NPM1 and CEBPA are included in validated schemas, while FLT3 ITD's inclusion is not explicitly stated but implied by its prognostic impact."}, "refers_back_to": null}], "task_complexity": "low", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-18", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "A large number of molecular alterations are under study for their prognostic impact in AML . However , only FLT3 @-@ ITD , NPM1 , CEBPA and c @-@ KIT are currently included in validated international risk stratification schema . These are expected to increase rapidly in the near future . FLT3 internal tandem duplications ( ITDs ) have been shown to confer a poorer prognosis in AML with normal cytogenetics . Several FLT3 inhibitors have undergone clinical trials , with mixed results . Two other mutations - NPM1 and biallelic CEBPA are associated with improved outcomes , especially in people with normal cytogenetics and are used in current risk stratification algorithms .", "_validation_note": "<reasoning>"}
4
+ {"session_id": "atlas-6383871180", "tier": "text", "task_instruction": "Identify the factors that influence the clinical significance of c-KIT mutations in AML and explain their importance.", "source": "llm_generated", "grounded_in": "wikitext-103", "steps": [{"step_index": 0, "observation": {"text": "c-KIT mutations are prevalent in AML.", "image_path": null, "audio_path": null}, "reasoning": "The passage states that c-KIT mutations are prevalent, which suggests they are significant in the disease context.", "action": {"type": "text_response", "value": "Recognize prevalence as a key factor."}, "refers_back_to": null}, {"step_index": 1, "observation": {"text": "Tyrosine kinase inhibitors like imatinib and sunitinib are available.", "image_path": null, "audio_path": null}, "reasoning": "The availability of these inhibitors indicates that c-KIT mutations can be targeted therapeutically, enhancing clinical significance.", "action": {"type": "text_response", "value": "Note the therapeutic implications of c-KIT mutations."}, "refers_back_to": null}, {"step_index": 2, "observation": {"text": "Additional markers like RUNX1, ASXL1, and TP53 are associated with poor outcomes.", "image_path": null, "audio_path": null}, "reasoning": "The inclusion of these markers in recommendations suggests they play a role in prognosis, which ties into the clinical significance of c-KIT mutations.", "action": {"type": "text_response", "value": "Understand the role of other markers in prognosis."}, "refers_back_to": null}, {"step_index": 3, "observation": {"text": "The prognostic importance of other genes like DNMT3A, IDH1, IDH2 is less clear.", "image_path": null, "audio_path": null}, "reasoning": "While these genes are mutated, their impact on prognosis isn't as established, highlighting that c-KIT mutations have a more defined role.", "action": {"type": "text_response", "value": "Acknowledge the uncertainty around other genes' prognostic value."}, "refers_back_to": null}], "task_complexity": "high", "language": "en", "license": "CC-BY-SA-3.0", "date_created": "2026-08-18", "_structural_pass": true, "_structural_reason": "ok", "_repaired": false, "_seed_type": "wikitext", "_seed_content": "Researchers are investigating the clinical significance of c @-@ KIT mutations in AML . These are prevalent , and potentially clinically relevant because of the availability of tyrosine kinase inhibitors , such as imatinib and sunitinib that can block the activity of c @-@ KIT pharmacologically . It is expected that additional markers ( e.g. , RUNX1 , ASXL1 , and TP53 ) that have consistently been associated with an inferior outcome will soon be included in these recommendations . The prognostic importance of other mutated genes ( e.g. , DNMT3A , IDH1 , IDH2 ) is less clear .", "_validation_note": "<reason for each step as explained above>"}